Vanderbilt-Ingram website >
A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.
Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.
Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer.
Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, was recruited to VUMC from The University of Texas MD Anderson Cancer Center in Houston.
Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.